Financial Performance - Total turnover for the six months ended September 30, 2021, was HK$87,492,000, a decrease of 4.9% compared to HK$91,746,000 in the same period of 2020[9]. - Gross profit for the period was HK$8,813,000, down 37.5% from HK$14,059,000 in the previous year[9]. - Operating loss for the period was HK$3,732,000, compared to an operating profit of HK$3,185,000 in the same period of 2020[9]. - The net loss for the period was HK$4,590,000, a significant decline from a profit of HK$1,746,000 in the prior year[9]. - Total comprehensive income for the period was a loss of HK$1,147,000, compared to a comprehensive income of HK$13,790,000 in the same period of 2020[11]. - Basic and diluted loss per share was HK$0.36, compared to a restated profit of HK$0.03 per share in the previous year[11]. - The Group's loss for the six months ended 30 September 2021 was approximately HK$4.59 million, a decrease of approximately HK$6.34 million compared to a profit of HK$1.75 million in the previous interim period[99]. - The decrease in loss was primarily due to reduced revenue from both healthcare services and money lending businesses, along with increased administrative expenses primarily from higher staff costs[99]. Assets and Liabilities - Non-current assets decreased from HK$1,129,000 to HK$777,000, a decline of approximately 31.2%[13]. - Current assets increased from HK$258,775,000 to HK$269,640,000, an increase of about 4.5%[13]. - Net current assets rose from HK$228,453,000 to HK$230,948,000, reflecting a growth of 1.1%[13]. - Total equity attributable to owners of the Company decreased slightly from HK$290,582,000 to HK$289,524,000, a decrease of 0.4%[13]. - The company’s total liabilities increased from HK$30,322,000 to HK$38,692,000, an increase of approximately 27.8%[13]. - As of September 30, 2021, the Group had bank balances and cash of approximately HK$21.17 million, an increase from approximately HK$8.57 million as of March 31, 2021[116]. - The Group had no borrowings as of September 30, 2021, resulting in a gearing ratio of 0[116]. Revenue Segments - The healthcare products and services business is one of the three operating segments, alongside money lending and securities trading and investments[33]. - The healthcare products and services business remains the largest contributor to the Group's revenue, although it experienced a slight decline due to the ongoing effects of the COVID-19 pandemic[100]. - For the healthcare segment, turnover was HK$86.74 million, down from HK$90.20 million in the same period last year, with segment profit decreasing to HK$3.81 million from HK$10.23 million[107]. - The money lending business recorded a turnover of interest income of HK$0.76 million for the six months ended 30 September 2021, down from HK$1.54 million for the same period in 2020[109]. Operational Efficiency and Strategy - The company is focusing on improving operational efficiency and exploring new market opportunities to enhance future performance[10]. - The Group intends to diversify its genetic testing and health data analysis products and expand into international markets to provide more comprehensive services[107]. - The Group's financial performance indicates a robust growth trajectory, supported by increased receivables and effective credit management strategies[67]. - The overall financial performance reflects challenges faced in the healthcare sector, necessitating strategic adjustments to enhance revenue streams and operational efficiency[100]. Corporate Governance and Compliance - The Group's financial statements are prepared in accordance with Hong Kong Accounting Standard 34, ensuring compliance with relevant disclosure requirements[25]. - The Group has not applied any new or revised HKFRSs that are not yet effective for the current interim period, maintaining consistency in accounting policies[25]. - The Board has approved the unaudited condensed consolidated financial statements for the six months ended 30 September 2021, prepared in accordance with generally accepted accounting standards in Hong Kong[114]. - The Group's independent audit committee reviewed the unaudited condensed consolidated financial statements for the six months ended September 30, 2021[121]. - The company confirmed compliance with the Model Code for Securities Transactions by Directors during the six months ended September 30, 2021[125]. - The company has taken sufficient measures to ensure corporate governance practices comply with the corporate governance code[126]. Shareholder Information - The substantial shareholders included Pang Zhen with 22.18% (285,004,080 shares), Zhou Chunyan with 19% (244,212,611 shares), and Pioneer Environmental International Industries Company Limited with 12.46% (160,120,000 shares)[132]. - The company adopted a new Share Option Scheme on September 18, 2012, valid for ten years, allowing the issuance of up to 107,085,706 shares upon exercise of options[136]. - No share options were exercised during the six months ended September 30, 2021, leaving 86,040,000 options outstanding[139]. - The refreshment of the scheme mandate limit was approved on September 7, 2018, allowing for the issuance of 535,428,530 shares, representing 10% of the issued shares at that time[138]. Changes in Management - Ms. Zheng Xin resigned as an independent non-executive director on 31 August 2021[142]. - Mr. Li Li was appointed as an independent non-executive director on 31 August 2021[142]. - Mr. Man Wai Lun was appointed as an independent non-executive director of Momentum Financial Holdings Limited on 27 August 2021[142]. - Mr. Man Wai Lun was appointed as an executive director of Century Group International Holdings Limited on 1 October 2021[142].

nd 100 莲机医疗 Life Healthcare ANI 年 Life Healthcare Group Limited 蓮和醫療健康集團有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代碼 :00928 HIMMANNA WANNA PECIEL HITT 蓮和醫療健康集團有限公司 2021年年度報告 Contents 目錄 Corporate Information 公司資料 2 Management Discussion and Analysis 管理層討論及分析 4 Biographical Details of Directors 董事履歷詳情 18 Directors' Report 董事會報告 21 Corporate Governance Report 企業管治報告 40 Environmental, Social and Governance Report 環境、社會及管治報告 56 Independent Auditor's Report 獨立 ...

Financial Performance - Total revenue for the six months ended September 30, 2020, was HK$91,746,000, a significant increase from HK$6,810,000 in the same period of 2019[12]. - Gross profit for the period was HK$14,059,000, compared to HK$5,320,000 in the previous year, reflecting a substantial improvement[12]. - Operating profit for the period was HK$3,185,000, a recovery from an operating loss of HK$12,406,000 in the prior year[12]. - Profit for the period attributable to owners of the company was HK$376,000, compared to a loss of HK$12,454,000 in the same period of 2019[12]. - Total comprehensive income for the period was HK$13,790,000, a significant recovery from a total comprehensive loss of HK$26,204,000 in the previous year[15]. - Earnings per share for the period was HK$0.03, a recovery from a loss of HK$1.16 per share in the same period of 2019[15]. - Profit before taxation for the six months ended September 30, 2020, was HK$3,185,000, compared to a loss of HK$12,406,000 in the same period of 2019[54]. - The profit for the interim period was approximately HK$1.75 million, an increase of approximately HK$14.20 million compared to a loss of HK$12.45 million in the previous interim period[136]. Revenue Segmentation - For the six months ended September 30, 2020, the Group's turnover and results are segmented into three main operating segments: healthcare products and services, money lending, and securities trading and investments[40]. - The Group's genetic testing segment recorded a turnover of HK$90.20 million for the six months ended 30 September 2020, a significant increase from HK$2.57 million in the same period of 2019[139]. - The money lending business recorded a turnover of interest income of HK$1.54 million for the six months ended 30 September 2020, down from HK$4.24 million in the same period of 2019[141]. Expenses and Costs - Other income and gains amounted to HK$462,000, while selling and distribution costs were HK$1,596,000[12]. - Administrative and other expenses totaled HK$6,927,000, indicating a decrease from HK$15,092,000 in the previous year[12]. - The company reported finance costs of HK$64,000, down from HK$176,000 in the prior year[12]. - The Group reported unallocated expenses of HK$4,813,000 for the current period, compared to HK$2,833,000 in the previous year[48]. Assets and Liabilities - As of September 30, 2020, total assets less current liabilities increased to HK$293,626,000 from HK$250,370,000 as of March 31, 2020, representing a growth of approximately 17.3%[17]. - Net current assets rose to HK$221,861,000, up from HK$211,878,000, indicating an increase of about 4.4%[17]. - The company's equity attributable to owners increased to HK$289,703,000 from HK$247,431,000, reflecting a growth of approximately 16.9%[21]. - Total cash and cash equivalents decreased to HK$19,322,000 from HK$194,123,000, a decline of about 90.1%[30]. - The net cash used in operating activities was HK$172,135,000, compared to a net cash generated of HK$185,229,000 in the previous year[30]. - Loan interest receivables increased to HK$3,945,000 from HK$2,402,000, representing a growth of about 64.3%[17]. - Trade receivables decreased significantly to HK$9,054,000 from HK$47,818,000[97]. - The total trade and other payables decreased to HK$29,280,000 from HK$51,143,000, indicating a reduction of 42.7%[113]. Share Capital and Dividends - The company did not declare or propose any dividends during both interim periods[71]. - The weighted average number of ordinary shares increased to 1,123,521,000 as of September 30, 2020, from 1,070,857,000 in 2019, reflecting a post-share consolidation adjustment[71]. - The company issued 1,070,840 ordinary shares on August 17, 2020, raising HK$10,708,000 in capital[126]. - Following a share consolidation, the number of ordinary shares decreased from 5,354,285 to 1,285,025 as of September 30, 2020[126]. Corporate Governance and Compliance - The Group's financial statements are prepared in accordance with Hong Kong Accounting Standard 34, ensuring compliance with applicable disclosure requirements[38]. - The Group has adopted revised HKFRSs for the first time, which did not result in significant changes to accounting policies or financial statement presentation[39]. - The Board did not recommend the payment of an interim dividend for the six months ended 30 September 2020, consistent with the previous year[153]. - The Company has complied with the Corporate Governance Code during the six months ended 30 September 2020, with some deviations noted[155]. Management and Strategy - The company continues to focus on expanding its market presence and enhancing its product offerings in the healthcare sector[12]. - The Group intends to enlarge and diversify its genetic testing and health data analysis products, as well as develop international business for comprehensive customer services[139]. - The management remains cautious in granting new loans due to prevailing market conditions, particularly the COVID-19 epidemic[141]. - The Group aims to maximize returns to shareholders by seeking new business opportunities and investment projects[141]. Employee and Operational Insights - As of September 30, 2020, the Group employed 16 employees, an increase from 10 employees as of September 30, 2019[144]. - The Group's interim report for 2020 provides insights into its operational segments and financial performance for the first half of the fiscal year[40].

Business Strategy and Operations - The Group reported a commitment to genetic testing and health data analysis services, aiming to provide a full range of medical and health administration solutions[8] - Since October 2019, the Group has shifted its business strategy to expand sales through third-party agents, currently covering 31 provinces in China[8] - The Group has reduced costs by outsourcing data extraction to a professional service provider, allowing technicians to focus on cancer detection genetic testing[8] - The Group is expanding sales channels for p-hydroxyphenylalanine urine testing products and plans to introduce them in 10 pilot cities across China[12] - The Group has entered into a strategic cooperation agreement with The Alliance of Chronic Disease Big Data Application to explore new healthcare management methods until December 31, 2023[12] - The Group is also engaged in money lending and securities trading businesses, diversifying its revenue streams[16] - The Group plans to set up trial platforms in different locations to explore and implement big data collection and healthcare management[12] - The Group's genetic testing, urine chemical testing, and medical products businesses are complementary, allowing for cross-selling and expansion of the sales network[36] - The Group aims to leverage big data to analyze customer demand and consumption behavior to enhance marketing strategies and increase revenues[36] - The Group is focused on cross-selling products across its various healthcare businesses to achieve economies of scale and increase revenue[39] Financial Performance - For the year ended 31 March 2020, the Group recorded a revenue of approximately HK$63.81 million, a slight increase from HK$63.49 million in the previous year[20] - The Group's gross profit for the year was approximately HK$12.10 million, with a gross profit margin of 18.97%, down from 55.92% in the previous year[24] - The loss for the year ended 31 March 2020 was approximately HK$23.72 million, representing a decrease of approximately 80.72% compared to the loss of HK$123.04 million in the previous year[24] - Basic and diluted loss per share for the year was approximately HK$0.46, a decrease of approximately 79.37% from HK$2.23 in the previous year[24] - For the year ended 31 March 2020, the healthcare products and services segment recorded a turnover of HK$58.06 million, representing an increase of approximately 19.5% compared to HK$48.59 million for the year ended 31 March 2019[28] - The segment loss for healthcare products and services was HK$12.92 million, a significant decrease from a loss of HK$74.33 million in the previous year, indicating improved performance[28] - Interest income from the money lending business decreased by approximately 61.48% to HK$5.74 million from HK$14.90 million in the previous year due to a downsized loan portfolio[28] - The gross profit rate for the money lending business was 100% as funding was sourced from internal resources, eliminating the need for finance costs[28] - The Group recorded a full impairment of approximately HK$20.86 million on an investment in a fund due to uncertainties surrounding the fund manager's operations[31] - An impairment of approximately HK$7.3 million was provided for interest in an associate for the year ended 31 March 2020[35] - The reserves available for distribution to shareholders as of March 31, 2020, amounted to approximately HK$247.43 million[79] Market and Industry Insights - The healthcare business became the largest contributor to the Group's revenue last year, reflecting its growing importance[26] - The directors believe that the healthcare products and services businesses have great prospects due to rising health awareness and improved quality of life in the PRC and globally[37] - The healthcare products and services business is expected to generate significant returns for the company and its shareholders due to the increasing health awareness and improved quality of life in China and globally[39] - The Board anticipates that the healthcare services market, particularly in genetic testing and health data analysis, is a new but growing field in the PRC[118] Corporate Governance and Management - The Board does not recommend the payment of a dividend for the year ended March 31, 2020 (2019: Nil)[77] - The Company has complied with the Corporate Governance Code during the year ended 31 March 2020, except for certain deviations regarding non-executive directors' terms[175] - The Board has established three committees: the Audit Committee, the Remuneration Committee, and the Nomination Committee[185] - Each independent non-executive director confirmed their independence in accordance with the Listing Rules[186] - The Company has implemented a comprehensive induction program for newly appointed directors to ensure understanding of the Group's operations and responsibilities[196] - The Company has committed to continuous professional development for directors, covering relevant knowledge and skills[198] - The roles of the chairman and the chief executive officer are separate, ensuring effective leadership and management oversight[192] - The board composition reflects a balance of legal, financial, and management expertise[199] Risks and Challenges - The Group's business faces principal risks including economic, operational, regulatory, and financial risks that could materially affect future results[123] - The Group faces significant economic risks, including a severe or prolonged downturn in the global or PRC economy, which could negatively impact operational, financing, or investing activities[127] - An increase in interest rates may adversely affect the Group's money lending business, increasing funding costs for borrowers and lowering profit margins, potentially impacting their repayment ability[128] - Regulatory risks include the need to obtain and maintain relevant licenses for healthcare services in PRC; failure to do so could adversely affect operations[137] - Changes in laws and regulations may affect the legality and enforceability of VIE agreements, which could impact the Group's control over its operations and economic benefits[139] Employee and Environmental Policies - The company provides comprehensive benefits and career development opportunities to its employees[141] - The group is committed to minimizing its environmental impact from business activities[141] - The group emphasizes quality assurance checks to ensure only quality products and services are offered to customers[141] Shareholder Information - The Company has maintained a sufficient public float as required under the Listing Rules[172] - The Company has a share option scheme but no other equity-linked agreements were entered into during the year[143] - The Group had no connected transactions or continuing connected transactions with its connected persons during the year ended March 31, 2020[165] - The Company maintained Directors and officers liability insurance during the year ended March 31, 2020[168]

Financial Performance - For the six months ended September 30, 2019, the company reported a turnover of HK$6,810,000, a decrease of 84.6% compared to HK$44,024,000 in the same period of 2018[12]. - The gross profit for the same period was HK$5,320,000, down from HK$28,483,000, reflecting a significant decline in profitability[12]. - The loss before taxation for the period was HK$12,406,000, compared to a loss of HK$69,012,000 in the previous year, indicating an improvement in financial performance[12]. - The total comprehensive expense for the period was HK$26,204,000, a decrease from HK$86,321,000 in the prior year, showing a reduction in overall losses[14]. - The loss attributable to equity holders of the company from continuing operations was HK$12,454,000, compared to HK$67,863,000 in the same period last year, indicating a narrowing of losses[12]. - The company reported a basic and diluted loss per share of HK$0.23 for the period, consistent with the previous year's loss per share[12]. - The company reported a loss for the period of HK$12,454,000, compared to a loss of HK$65,359,000 in the previous period[26]. - The segment loss for continuing operations was HK$29,915,000, with a significant impairment loss on interest in an associate amounting to HK$17,080,000[107]. - The Group's loss for the interim period was approximately HK$12.45 million, a decrease of approximately 81.40% from HK$66.95 million in the previous interim period[185]. Cost Management - The administrative and other expenses amounted to HK$15,092,000, a decrease from HK$39,251,000 in the prior year, reflecting cost control measures[12]. - The company experienced a significant reduction in selling and distribution costs, which totaled HK$31,627,000, down from HK$15,541,000 in the previous year[12]. - The overall financial position shows a positive trend with increased cash reserves and improved cash flow from operations[45]. Assets and Liabilities - As of September 30, 2019, total assets less current liabilities amounted to HK$264,306,000, a decrease of 8.34% from HK$288,341,000 as of March 31, 2019[15]. - Current assets decreased to HK$222,113,000 from HK$240,519,000, reflecting a decline of 7.66%[15]. - The company's net current assets were HK$207,426,000, down from HK$228,274,000, indicating a decrease of 9.12%[15]. - Non-current assets totaled HK$56,880,000, a decrease of 5.67% from HK$60,067,000[15]. - Total equity attributable to owners of the Company was HK$262,137,000, down from HK$288,341,000, reflecting a decrease of 9.09%[19]. - The reserves decreased to HK$208,594,000 from HK$234,798,000, a decline of 11.14%[19]. - The interest in associates decreased to HK$30,898,000 from HK$35,783,000, a reduction of 13.76%[15]. - The company's inventories decreased to HK$1,552,000 from HK$1,856,000, indicating a decline of 16.38%[15]. Cash Flow - Net cash generated from operating activities was HK$185,229, compared to a cash outflow of HK$34,267 in the same period last year[45]. - Net cash generated from investing activities was HK$161, a significant improvement from a cash outflow of HK$1,091 in the previous year[45]. - Cash and cash equivalents at 30 September amounted to HK$194,123, an increase from HK$36,757 at the same time last year[45]. - The effect of foreign exchange rate changes contributed HK$21,065 to cash and cash equivalents, compared to a negative impact of HK$10,755 in the previous year[45]. Business Segments - The company is primarily engaged in healthcare services, money lending, and securities trading and investment[49]. - The healthcare services segment generated external sales of HK$2,570,000, while the money lending business reported external sales of HK$4,240,000[100]. - The Group's operating segments include healthcare services, money lending, and securities trading and investments[100]. - The healthcare services segment recorded a turnover of HK$2.57 million, down from HK$38.12 million in the previous year, with a segment loss of HK$7.24 million[190]. - The money lending business generated a turnover of interest income of HK$4.24 million, down from HK$5.90 million in the previous year, maintaining a gross profit margin of 100%[192]. Future Outlook - The company is focusing on improving operational efficiency and reducing costs to enhance future profitability[12]. - The management expressed optimism about future performance improvements as the company implements new strategies and operational adjustments[12]. - The Group plans to enhance its sales strategy by focusing on distributor sales to penetrate major cities in the PRC, which may temporarily affect revenue during the transition[190]. - The Group aims to expand and diversify its genetic testing and health data analysis products to provide more comprehensive services to customers[190]. - The management will continue to seek new business opportunities and investment projects suitable for the Company[195]. Compliance and Accounting - The financial statements are prepared in accordance with Hong Kong Accounting Standard 34, ensuring compliance with applicable disclosure requirements[49]. - The company adopted new accounting standards effective from 1 April 2019, including HKFRS 16 on leases, which may impact future financial reporting[53]. - The Group adopted HKFRS 16 from April 1, 2019, recognizing lease liabilities previously classified as operating leases[60]. - The Group did not restate comparative information for the 2018 reporting period as permitted under the simplified transition approach[60]. - The Board has approved the unaudited condensed consolidated financial statements for the six months ended September 30, 2019, prepared in accordance with Hong Kong generally accepted accounting standards[200].